相关实验视频

Updated: Jan 17, 2026

The Lambda Select cII Mutation Detection System

The Lambda Select cII Mutation Detection System

Published on: April 26, 2018

由于有限的低位信息要求,REACH规范中遗漏了多少变异原体?

Rune Hjorth¹, Joop de Knecht², Eva B Wedebye³

¹DTU Sustain, Technical University of Denmark, Kgs. Lyngby, Denmark.

Regulatory toxicology and pharmacology : RTP

|September 24, 2025

概括

许多变异原体在低位的REACH注册中被遗漏,因为只需要Ames测试. 包括体外微核试验在内,可以提高每年1-10范围内的突变性物质的识别.

科学领域:

化学安全评估化学安全评估
毒理学毒理学毒理学
监管科学是一种监管科学.

背景情况:

REACH法规仅要求使用艾姆斯试验来评估工业物质1-10/年的变异性.
阴性艾姆斯测试结果可能会阻止进一步的突变性测试,可能会缺少一些突变原体.
根据 (Q) SAR 建模,丹麦环保署提供了对变异性进行咨询的自我分类 (ASC).

研究的目的:

为了将物质与ASC进行低量REACH注册中的已识别的原体的变异性比较.
评估REACH.根据现行变异性测试要求的有效性.
建议改进在较低量级别识别变异性物质的方法.

主要方法:

与Muta. 的物质比较. 在低位的REACH注册中,ASC对实验性的Ames测试结果.
分析REACH档案中可用的体外和体内致变性数据.
(Q) SAR建模用于咨询自我分类.

主要成果:

只有大约四分之一的低量物质具有突变. 2 ASC显示Ames测试结果呈阳性,导致随访.
在每年1-10的注册水平上,可能有大量潜在的变异原体未被识别.
在低量档案中的体内微核试验数据通常由于缺乏暴露信息而没有确定性.

结论:

目前的REACH对低量物质的致变性测试要求不足以全面识别致变性物质.
应包括体外微核试验,以补充艾姆斯试验,以便在1-10/年范围内更好地识别突变性.
改善体内试验数据报告是必要的,以确保确的结果.

关键词:

(Q) 沙尔 (SAR) 的一个地方.艾姆斯试验的测试细菌逆转基因突变测试试验致变性致变性致变性在REACH系统中,我们可以使用REACH.

更多相关视频

Transgenic Rodent Assay for Quantifying Male Germ Cell Mutant Frequency

Transgenic Rodent Assay for Quantifying Male Germ Cell Mutant Frequency

Published on: August 6, 2014

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

相关概念视频

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

Mismatch Repair

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

Mismatch Repair

Mismatch Repair

Spontaneous and Induced Mutations

Spontaneous and Induced Mutations

Spontaneous mutations arise infrequently during DNA replication due to errors in the process. A key factor behind these errors is tautomeric shifts in nitrogenous bases, where bases transition from keto to enol forms or amino to imino forms. This shift can alter base-pairing rules, leading to mutations. Additionally, reactive oxygen species (ROS) arising from aerobic metabolism can damage DNA, resulting in depurination (loss of a purine base) or depyrimidination (loss of a pyrimidine base).

In-vitro Mutagenesis

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.